Mon, July 18, 2022
Sat, July 16, 2022
Fri, July 15, 2022
Thu, July 14, 2022

David Lebowitz Maintained (ALNY) at Hold with Decreased Target to $164 on, Jul 15th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-164-on-jul-15th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Lebowitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $170 to $164 on, Jul 15th, 2022.

David has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Hold and Held Target at $175 on, Wednesday, July 13th, 2022
  • Debjit Chattopadhyay of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, June 27th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $98 on, Wednesday, June 15th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $170 on, Friday, April 29th, 2022
  • Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $166 on, Friday, April 29th, 2022


These are the ratings of the 2 analyists that currently disagree with David


  • Myles Minter of "William Blair" Initiated at Buy on, Tuesday, June 7th, 2022
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $430 on, Monday, May 2nd, 2022

Publication Contributing Sources